Vivet Therapeutics is delighted to announce its participation in the European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place in Sevilla, on October 7–10, 2025 (https://www.esgctcongress.com).

On Thursday, October 9, Vivet will present new data on VTX-PID, highlighting compelling clinical results that demonstrate a reduction of neutralizing antibodies against AAV in naturally immunized populations. These findings have important implications for expanding patient access to future gene therapies.

We look forward to connecting with colleagues, partners, and the broader scientific community in Sevilla